Other options include using THZ1 in antibody-based conjugates, a strategy that has worked well for glioma in initial clinical trials of ABT-414, an EGFRvIII-specific antibody conjugated to the cytotoxin monomethyl auristatin F.33 It will be important to test such possibilities for THZ1, as our data definitively show that if THZ1 can gain access to the tumor, CDK7 inhibition will be a potent and widely effective therapeutic option. Here, CDK7 is linked to glioma.